Rapiscan Pharma Solutions Overview

  • Founded
  • 2010
  • Status
  • Acquired/​Merged
  • Employees
  • 4
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $23.7M
Latest Deal Amount

Rapiscan Pharma Solutions General Information


Manufacturer of a pharmacological stress agent. The company's pharmacological stress agent simulates the effects of exercise in the hearts of adult patients and offers an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures. It is also used in the diagnosis of coronary artery disease (CAD), a common type of cardiovascular disease.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Parent Company
Primary Office
  • 530 Lytton Ave, 2nd floor
  • Palo Alto, CA 94301
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rapiscan Pharma Solutions Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 03-Jan-2017 $23.7M 00.000 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 24-Apr-2013 00.000 00.000 0000 Completed Startup
2. Early Stage VC (Series A2) 29-Dec-2011 $1000K $3.35M 00.000 Completed Startup
1. Early Stage VC (Series A) 25-Oct-2010 $2.35M $2.35M 00.000 Completed Startup
To view Rapiscan Pharma Solutions’s complete valuation and funding history, request access »

Rapiscan Pharma Solutions Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 000
Series A2 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 000
Series A 8,000,000 $0.000100 $0.02 $0.29 $0.29 1x $0.29 32%
To view Rapiscan Pharma Solutions’s complete cap table history, request access »

Rapiscan Pharma Solutions Board Members (3)

Name Representing Role Since
Daniel Spiegelman Self Co-Founder & Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Rapiscan Pharma Solutions Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rapiscan Pharma Solutions Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
To view Rapiscan Pharma Solutions’s complete investors history, request access »